Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer-Reference-Cited by-同舟云学术

Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer

Published:2015-09-03 Issue:1 Volume:24 Page:447-455
ISSN:0941-4355
Container-title:Supportive Care in Cancer
language:en
Short-container-title:Support Care Cancer

Author:

Stopeck Alison T.,Fizazi Karim,Body Jean-Jacques,Brown Janet E.,Carducci Michael,Diel Ingo,Fujiwara Yasuhiro,Martín Miguel,Paterson Alexander,Tonkin Katia,Shore Neal,Sieber Paul,Kueppers Frank,Karsh Lawrence,Yardley Denise,Wang Huei,Maniar Tapan,Arellano Jorge,Braun Ada

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00520-015-2904-5.pdf

Reference29 articles.

1. Kris MG, Benowitz SI, Adams S, Diller L, Ganz P, Kahlenberg MS, Le QT, Markman M, Masters GA, Newman L, Obel JC, Seidman AD, Smith SM, Vogelzang N, Petrelli NJ (2010) Clinical cancer advances 2010: annual report on progress against cancer from the American society of clinical oncology. J Clin Oncol 28:5327–5347

2. Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun A, Jun S (2012) Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 48:3082–3092

3. Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377:813–822

4. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28:5132–5139

5. Fallowfield L, Cleeland CS, Body JJ, Stopeck A, von Moos R, Patrick DL, Clemons M, Tonkin K, Masuda N, Lipton A, de Boer R, Salvagni S, Oliveira CT, Ying W, Braun A, Cong Z (2011) Pain severity and analgesic use associated with skeletal-related events in patients with advanced breast cancer and bone metastases. Cancer Res 71(Suppl 3):Abstract P4-13–01

Cited by 147 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Relationship between Medication-Related Osteonecrosis of the Jaw and CDK4/6 Inhibitors in Breast Cancer;Current Oncology;2024-01-01

2. Navigating the complexities and controversies of medication-related osteonecrosis of the jaw (MRONJ): a critical update and consensus statement;Acta Chirurgica Belgica;2023-12-08

3. Bone-Targeted Therapy Regimen and Skeletal-Related Events in Patients Surviving Longer Than 2 Years With Metastatic Breast Cancer and Bone Metastasis;Clinical Breast Cancer;2023-12

4. Femoral metastatic pathological fractures, impending and actual fractures – A patient survival study;Surgical Oncology;2023-12

5. Medication-Related Osteonecrosis of the Jaw: A Cross-Sectional Study on the Prevalence of Cutaneous Manifestations and the Primary Care Physician's Role in its Early Diagnosis;The American Journal of Medicine;2023-12